New combo attack: radiation plus surgery for stubborn tumors
NCT ID NCT04609592
First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This early-phase study is testing whether giving a radioactive drug called Lutathera both before and after surgery is safe for people with advanced neuroendocrine tumors that have spread to the liver or lymph nodes. The trial will enroll 10 adults whose tumors are considered removable by surgery. The main goal is to see if this combined approach can be done without serious complications, and to gather initial data on tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lutathera (lutetium Lu 177 dotatate)
- What this could lead to
- If successful, this could show that giving Lutathera before and after surgery is safe and may improve outcomes for people with certain neuroendocrine tumors.
- What could go wrong
- This is a very early, small phase 1 trial with only 10 participants. It focuses on safety and feasibility, not yet on effectiveness. There are risks from both the radiation and surgery, such as liver or bowel complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford Cancer Institute Palo Alto
Stanford, California, 95304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a black seed extract boost immunotherapy against a rare cancer?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Massive study to map Real-World GEP-NET care
- Could a liver artery shot make cancer treatment more effective?
- Double PET scan may unlock secrets of gut tumors
- New registry tracks PRRT outcomes for neuroendocrine cancer patients